Join leading experts for this year’s symposium focused on advancing personalized breast cancer care.
Hosted by the University of Michigan Health Rogel Cancer Center, the program will explore strategies to optimize treatment for patients with low-risk breast cancer while improving outcomes for those with high-risk, early-stage disease. Attendees will hear from Rogel Cancer Center faculty and nationally recognized breast cancer specialists as they share the latest evidence, emerging approaches, and practical insights to support high-quality, patient-centered care.
Don’t miss this opportunity to engage with experts, learn about advances in breast cancer management, and help shape the future of care.
Overview
Target Audience
- Specialties - Hematology/Oncology, Internal Medicine
- Professions - Medical Student, Nurse, Nurse Practitioner, Other Healthcare Professional, Physician, Physician Assistant, Physician Fellow, Physician Resident, Scientist
Credits
AMA PRA Category 1 Credits™ (5.75 hours), Non-Physician Attendance (5.75 hours)
Overview
The Michigan Medicine Rogel Cancer Center (UMRCC) is an NCI-designated comprehensive cancer center with a history of excellence in cancer care, education, and research. The UMRCC catchment area includes the entire State of Michigan, its ˜10M residents, and ˜750 community medical oncologists. The Mission of the UMRCC is to reduce the burden of cancer and advance health equity through transdisciplinary collaboration in research, education, patient care and community outreach. The mission of the University of Michigan Rogel Cancer Center is to reduce the burden of cancer and advance health equity through transdisciplinary collaboration in research, education, patient care and community outreach. Join us for an engaging educational session by the University of Michigan Rogel Cancer Center, designed to enhance your expertise in breast cancer care. Learn about the latest advances in local and systemic therapies, management of young-onset and metastatic breast cancer, strategies for handling treatment toxicities, and best practices for using ctDNA testing in clinical practice. Don’t miss this opportunity to improve outcomes for your patients!
Objectives
At the conclusion of this activity, learners will be able to:
- Apply evolving clinical trial data to breast cancer treatment decisions.
- Evaluate treatment options based on efficacy, toxicity, and patient-centered considerations.
- Integrate emerging therapies into clinical management of high-risk and complex cases.
- Implement evidence-based strategies to improve survivorship and manage treatment-related toxicities.
Accreditation
The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
AMA PRA Category 1
The University of Michigan Medical School designates this Live Activity for a maximum of 5.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Additional Information
Accessibility Statement
The University of Michigan Medical School is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008. If you have needs that require special accommodations, including dietary concerns, please contact the CME Activity Coordinator.